Evolus Quarterly Balance Sheets Chart
Quarterly
|
Annual
Evolus Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||||||||
| current assets | |||||||||||||||||||||||||||||||
| cash and cash equivalents | 61,738,000 | 67,894,000 | 86,952,000 | 85,035,000 | 93,671,000 | 96,958,000 | 62,838,000 | 38,685,000 | 41,705,000 | 31,463,000 | 53,922,000 | 65,572,000 | 84,484,000 | 106,671,000 | 146,256,000 | 107,796,000 | 131,737,000 | 22,171,000 | 102,562,000 | 85,127,000 | 29,772,000 | 34,652,000 | 109,892,000 | 39,116,000 | 30,289,000 | 54,367,000 | 49,570,000 | ||||
| accounts receivable | 47,709,000 | 47,454,000 | 47,682,000 | 44,642,000 | 43,149,000 | 34,240,000 | 30,529,000 | 30,464,000 | 28,996,000 | 23,455,000 | 22,448,000 | 20,920,000 | 21,026,000 | 16,800,000 | 14,657,000 | 13,289,000 | 11,864,000 | 7,816,000 | 9,680,000 | 11,399,000 | 8,649,000 | 10,406,000 | 10,661,000 | 7,206,000 | 1,410,000 | ||||||
| inventories | 26,457,000 | 10,026,000 | 12,158,000 | 14,892,000 | 13,381,000 | 11,547,000 | 10,998,000 | 17,626,000 | 19,859,000 | 23,418,000 | 18,852,000 | 21,565,000 | 12,289,000 | 3,615,000 | 1,762,000 | 3,816,000 | 3,337,000 | 2,775,000 | 3,354,000 | 4,871,000 | 10,343,000 | 12,542,000 | 6,407,000 | 10,043,000 | 11,522,000 | 2,578,000 | |||||
| prepaid expenses | 4,792,000 | 3,452,000 | 3,349,000 | 3,399,000 | 5,507,000 | 5,678,000 | 5,700,000 | 3,655,000 | 4,297,000 | 4,159,000 | 3,902,000 | 3,656,000 | 4,724,000 | 4,533,000 | 5,082,000 | 4,484,000 | 5,737,000 | 5,464,000 | |||||||||||||
| other current assets | 4,274,000 | 2,892,000 | 1,201,000 | 2,393,000 | 2,426,000 | 1,842,000 | 2,356,000 | 1,569,000 | 1,603,000 | 1,590,000 | 1,678,000 | 4,233,000 | 11,424,000 | 11,309,000 | 11,042,000 | 8,959,000 | 9,215,000 | 6,728,000 | |||||||||||||
| total current assets | 144,970,000 | 131,718,000 | 151,342,000 | 150,361,000 | 158,134,000 | 150,265,000 | 112,421,000 | 91,999,000 | 96,460,000 | 84,085,000 | 100,802,000 | 115,946,000 | 133,947,000 | 142,928,000 | 178,799,000 | 138,344,000 | 161,890,000 | 77,717,000 | 127,612,000 | 132,400,000 | 107,998,000 | 126,142,000 | 152,197,000 | 95,184,000 | 115,826,000 | 139,084,000 | 94,339,000 | 106,092,000 | 44,623,000 | 50,111,000 | 72,824,000 |
| property and equipment | 3,653,000 | 3,254,000 | 3,222,000 | 2,314,000 | 2,284,000 | 2,088,000 | 2,087,000 | 2,130,000 | 2,353,000 | 2,595,000 | 2,616,000 | 1,882,000 | 1,455,000 | 1,303,000 | 1,371,000 | 1,058,000 | 1,137,000 | 1,217,000 | 1,297,000 | 1,362,000 | 1,422,000 | 1,433,000 | 902,000 | 984,000 | 290,000 | 1,000 | 5,000 | ||||
| operating lease right-of-use assets | 7,827,000 | 6,922,000 | 7,185,000 | 8,280,000 | 5,462,000 | 5,615,000 | 5,763,000 | 5,907,000 | 1,523,000 | 1,738,000 | 1,947,000 | 2,149,000 | 2,346,000 | 2,537,000 | 2,722,000 | 2,902,000 | 3,078,000 | 3,248,000 | 3,414,000 | 3,578,000 | 3,738,000 | 3,899,000 | 4,068,000 | 4,238,000 | 5,040,000 | 810,000 | |||||
| intangible assets | 49,347,000 | 49,359,000 | 48,754,000 | 46,587,000 | 46,275,000 | 46,591,000 | 47,110,000 | 46,505,000 | 47,216,000 | 47,927,000 | 48,597,000 | 49,108,000 | 49,415,000 | 50,032,000 | 50,625,000 | 51,468,000 | 52,310,000 | 53,568,000 | 55,297,000 | 56,791,000 | 58,023,000 | 59,174,000 | 59,638,000 | 59,857,000 | 59,211,000 | 58,782,000 | |||||
| goodwill | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 | 21,208,000 |
| other assets | 1,798,000 | 900,000 | 858,000 | 858,000 | 409,000 | 409,000 | 409,000 | 222,000 | 223,000 | 2,682,000 | 2,813,000 | 2,426,000 | 2,548,000 | 2,654,000 | 2,758,000 | 240,000 | 240,000 | 240,000 | 240,000 | 440,000 | 2,155,000 | 2,295,000 | 2,429,000 | 1,195,000 | 1,206,000 | 1,045,000 | 221,000 | 22,000 | 2,125,000 | ||
| total assets | 228,803,000 | 213,361,000 | 232,569,000 | 229,608,000 | 233,772,000 | 226,176,000 | 188,998,000 | 167,971,000 | 168,983,000 | 160,235,000 | 177,983,000 | 192,719,000 | 210,919,000 | 220,662,000 | 257,483,000 | 215,220,000 | 239,863,000 | 157,198,000 | 209,068,000 | 215,779,000 | 194,544,000 | 214,151,000 | 240,442,000 | 182,666,000 | 202,781,000 | 220,929,000 | 171,844,000 | 183,377,000 | 121,934,000 | 127,395,000 | 152,233,000 |
| liabilities and stockholders’ equity | |||||||||||||||||||||||||||||||
| current liabilities | |||||||||||||||||||||||||||||||
| accounts payable | 23,312,000 | 16,176,000 | 9,236,000 | 13,836,000 | 10,281,000 | 11,216,000 | 4,271,000 | 11,760,000 | 7,835,000 | 10,185,000 | 8,935,000 | 8,564,000 | 10,486,000 | 7,565,000 | 6,091,000 | 7,365,000 | 8,059,000 | 13,253,000 | 9,615,000 | 2,957,000 | 10,952,000 | 10,699,000 | 5,796,000 | 6,125,000 | 1,863,000 | 1,558,000 | 661,000 | 751,000 | 547,000 | 445,000 | |
| accrued expenses | 27,949,000 | 26,619,000 | 40,791,000 | 34,949,000 | 32,790,000 | 25,054,000 | 33,813,000 | 26,713,000 | 24,184,000 | 22,109,000 | 24,794,000 | 29,883,000 | 28,537,000 | 21,139,000 | 29,993,000 | 23,436,000 | 24,357,000 | 12,567,000 | 9,102,000 | 6,425,000 | 6,094,000 | 9,403,000 | 13,960,000 | 14,378,000 | 6,735,000 | 3,718,000 | 4,799,000 | 2,933,000 | 2,352,000 | 977,000 | |
| current portion of operating lease liabilities | 2,392,000 | 1,031,000 | |||||||||||||||||||||||||||||
| current portion of contingent royalty obligation payable to evolus founders | 10,097,000 | ||||||||||||||||||||||||||||||
| total current liabilities | 63,750,000 | 56,233,000 | 62,960,000 | 60,815,000 | 54,118,000 | 46,801,000 | 48,291,000 | 48,540,000 | 41,349,000 | 40,678,000 | 46,509,000 | 51,271,000 | 51,531,000 | 40,700,000 | 57,663,000 | 71,303,000 | 87,286,000 | 87,648,000 | 180,248,000 | 12,709,000 | 19,462,000 | 22,613,000 | 24,439,000 | 25,974,000 | 23,105,000 | 9,400,000 | 5,276,000 | 5,460,000 | 3,684,000 | 3,629,000 | 212,748,000 |
| long-term portion of operating lease liabilities | 7,039,000 | ||||||||||||||||||||||||||||||
| long-term portion of contingent royalty obligation payable to evolus founders | 28,489,000 | ||||||||||||||||||||||||||||||
| long-term portion of term loan, net of discount and issuance costs | 145,475,000 | ||||||||||||||||||||||||||||||
| contingent milestone payment | 2,681,000 | 2,416,000 | 2,270,000 | ||||||||||||||||||||||||||||
| deferred tax liability | 21,000 | 2,000 | 6,000 | 29,000 | 29,000 | 32,000 | 27,000 | 22,000 | 22,000 | 22,000 | 22,000 | 25,000 | 29,000 | 23,000 | 40,000 | 25,000 | 25,000 | 25,000 | 25,000 | 179,000 | 190,000 | 256,000 | 156,000 | 305,000 | 533,000 | 15,055,000 | 15,031,000 | 15,013,000 | 15,000,000 | 14,990,000 | |
| total liabilities | 247,455,000 | 219,965,000 | 227,047,000 | 223,718,000 | 214,458,000 | 207,733,000 | 209,687,000 | 187,339,000 | 175,946,000 | 153,286,000 | 159,484,000 | 163,499,000 | 164,058,000 | 153,414,000 | 175,607,000 | 117,816,000 | 133,725,000 | 133,909,000 | 282,026,000 | 180,684,000 | 150,941,000 | 151,545,000 | 160,985,000 | 165,623,000 | 161,600,000 | 145,572,000 | 87,460,000 | 88,411,000 | 83,999,000 | 75,413,000 | 227,776,000 |
| commitments and contingencies | |||||||||||||||||||||||||||||||
| stockholders’ equity | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of june 30, 2025 and december 31, 2024, respectively | |||||||||||||||||||||||||||||||
| common stock | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |
| additional paid-in capital | 627,379,000 | 622,525,000 | 615,825,000 | 609,186,000 | 603,352,000 | 591,087,000 | 538,716,000 | 528,385,000 | 523,729,000 | 519,449,000 | 516,129,000 | 513,717,000 | 510,879,000 | 507,733,000 | 504,757,000 | 502,108,000 | 491,409,000 | 392,959,000 | 303,113,000 | 300,469,000 | 297,502,000 | 295,174,000 | 292,509,000 | 215,574,000 | 212,704,000 | 209,365,000 | 207,408,000 | 205,548,000 | 136,687,000 | 134,301,000 | |
| accumulated other comprehensive loss | -599,000 | -839,000 | -905,000 | -689,000 | -601,000 | -557,000 | -427,000 | -606,000 | -468,000 | -416,000 | -337,000 | -368,000 | -165,000 | -103,000 | -9,000 | ||||||||||||||||
| accumulated deficit | -645,433,000 | -628,291,000 | -609,399,000 | -602,608,000 | -583,438,000 | -572,088,000 | -558,979,000 | -547,148,000 | -530,225,000 | -512,085,000 | -497,294,000 | -484,130,000 | -463,854,000 | -440,383,000 | -422,882,000 | -404,705,000 | -385,272,000 | -369,671,000 | -376,072,000 | -265,378,000 | -253,919,000 | -232,794,000 | -213,059,000 | -198,551,000 | -171,567,000 | -134,000,000 | -123,025,000 | -110,583,000 | -98,753,000 | -82,320,000 | -75,543,000 |
| total stockholders’ equity | -18,652,000 | -6,604,000 | 5,522,000 | 5,890,000 | 19,314,000 | 18,443,000 | -20,689,000 | -19,368,000 | -6,963,000 | 6,949,000 | 18,499,000 | 29,220,000 | 46,861,000 | 67,248,000 | 81,876,000 | 97,404,000 | 106,138,000 | 23,289,000 | 35,095,000 | 43,603,000 | 62,606,000 | 79,457,000 | 17,043,000 | 41,181,000 | 75,357,000 | 84,384,000 | 94,966,000 | 37,935,000 | 51,982,000 | ||
| total liabilities and stockholders’ equity | 228,803,000 | 213,361,000 | 232,569,000 | 229,608,000 | 233,772,000 | 226,176,000 | 188,998,000 | 167,971,000 | 168,983,000 | 160,235,000 | 177,983,000 | 192,719,000 | 210,919,000 | 220,662,000 | 257,483,000 | 215,220,000 | 239,863,000 | 157,198,000 | 215,779,000 | 194,544,000 | 214,151,000 | 240,442,000 | 182,666,000 | 202,781,000 | 220,929,000 | 171,844,000 | 183,377,000 | 121,934,000 | 127,395,000 | ||
| operating lease liabilities | 1,967,000 | 1,718,000 | 1,601,000 | 1,041,000 | 1,152,000 | 1,377,000 | 1,363,000 | 1,349,000 | 1,334,000 | 1,320,000 | 1,307,000 | 1,293,000 | 1,279,000 | 1,265,000 | 1,252,000 | 1,239,000 | 1,226,000 | 1,212,000 | 1,197,000 | 1,182,000 | 1,195,000 | 1,200,000 | 1,148,000 | 4,147,000 | 802,000 | ||||||
| contingent royalty obligation payable to evolus founders | 11,471,000 | 11,215,000 | 10,429,000 | 10,006,000 | 9,379,000 | 8,830,000 | 8,704,000 | 7,981,000 | 7,050,000 | 6,460,000 | 6,517,000 | 6,215,000 | 5,717,000 | 5,314,000 | 4,300,000 | 3,983,000 | 3,985,000 | 3,446,000 | 2,130,000 | 1,234,000 | 1,316,000 | 3,483,000 | 4,323,000 | 43,773,000 | |||||||
| term loan, net of discount and issuance costs | 121,807,000 | 121,506,000 | 121,208,000 | 120,918,000 | 120,636,000 | 120,359,000 | 95,094,000 | 94,829,000 | 72,046,000 | 71,879,000 | 71,712,000 | 71,545,000 | 71,381,000 | 74,384,000 | |||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2025 and december 31, 2024, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2024 and 2023, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||||||||
| accrued litigation settlement | 5,000,000 | 5,000,000 | 5,000,000 | 5,000,000 | 15,000,000 | 15,000,000 | 30,000,000 | 30,000,000 | |||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||||||||||
| short-term investments | 5,000,000 | 24,996,000 | 54,982,000 | 64,987,000 | 19,911,000 | 34,913,000 | 69,640,000 | 79,313,000 | |||||||||||||||||||||||
| promissory note payable to evolus founders | 19,950,000 | 19,648,000 | 19,354,000 | ||||||||||||||||||||||||||||
| convertible note | 40,506,000 | 40,203,000 | |||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||||||||
| term loan, net of discounts and issuance costs | 73,974,000 | ||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||||||||
| consideration receivable from daewoong | 25,500,000 | ||||||||||||||||||||||||||||||
| withholding tax receivable | 7,263,000 | ||||||||||||||||||||||||||||||
| withholding tax payable | 7,263,000 | ||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||||||||
| prepaid expenses and other current assets | 7,016,000 | 6,007,000 | 4,252,000 | 3,555,000 | 5,326,000 | 3,906,000 | 2,965,000 | 2,826,000 | 1,177,000 | 924,000 | 1,038,000 | 541,000 | 185,000 | ||||||||||||||||||
| liabilities and stockholders’ (deficit) equity | |||||||||||||||||||||||||||||||
| accrued litigation settlement expenses | 63,421,000 | ||||||||||||||||||||||||||||||
| contingent promissory note payable to evolus founders | 19,068,000 | 18,779,000 | 18,495,000 | 18,218,000 | 17,945,000 | 17,674,000 | 17,408,000 | ||||||||||||||||||||||||
| stockholders’ (deficit) equity | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||||||||
| accumulated other comprehensive gain | 3,000 | 19,000 | 225,000 | 6,000 | 19,000 | 43,000 | |||||||||||||||||||||||||
| total stockholders’ (deficit) equity | -72,958,000 | ||||||||||||||||||||||||||||||
| total liabilities and stockholders’ (deficit) equity | 209,068,000 | ||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||||||||
| long-term debt, net of discounts and issuance costs | 74,165,000 | 73,841,000 | 73,508,000 | 73,180,000 | 72,862,000 | 72,557,000 | |||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||||||||
| deferred rent | 25,000 | 29,000 | 32,000 | 35,000 | 38,000 | ||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2019 and december 31, 2018, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2019 and december 31, 2018, respectively | |||||||||||||||||||||||||||||||
| accounts payable and accrued expenses | 22,074,000 | ||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2019 and december 31, 2018, respectively | |||||||||||||||||||||||||||||||
| contingent royalty obligation payable to evolus founders, a related party | 45,900,000 | 50,200,000 | 51,100,000 | 48,800,000 | |||||||||||||||||||||||||||
| contingent promissory note payable to evolus founders, a related party | 17,153,000 | 16,904,000 | 16,791,000 | 16,470,000 | |||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2019 and december 31, 2018, respectively | |||||||||||||||||||||||||||||||
| cash | 93,162,000 | 105,168,000 | 43,585,000 | ||||||||||||||||||||||||||||
| related party receivable | 72,639,000 | ||||||||||||||||||||||||||||||
| intangible asset | 56,076,000 | 56,076,000 | 56,076,000 | 56,076,000 | 56,076,000 | ||||||||||||||||||||||||||
| related party borrowings | 72,639,000 | ||||||||||||||||||||||||||||||
| note obligation | 138,687,000 | ||||||||||||||||||||||||||||||
| convertible series a preferred, 0.00001 par value; no shares authorized; 0 and 1,250,000 shares issued and outstanding at december 31, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||
| convertible series a preferred, 0.00001 par value; no shares authorized; 0 and 1,250,000 shares issued and outstanding at september 30, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||
| convertible series a preferred, 0.00001 par value; no shares authorized; 0 and 1,250,000 shares issued and outstanding at june 30, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||
| related party accounts payable | 730,000 | ||||||||||||||||||||||||||||||
| contingent royalty obligation payable to related party | 40,600,000 | ||||||||||||||||||||||||||||||
| contingent promissory note payable to related party | 16,149,000 | ||||||||||||||||||||||||||||||
| convertible series a preferred, 0.00001 par value; no shares authorized; 0 and 1,250,000 shares issued and outstanding at march 31, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||
| restricted cash | |||||||||||||||||||||||||||||||
| liabilities and stockholder’s deficit | |||||||||||||||||||||||||||||||
| stockholder’s deficit | |||||||||||||||||||||||||||||||
| convertible series a preferred, 0.00001 par value; 2,500,000 shares authorized; 1,250,000 shares issued and outstanding at december 31, 2017 and 2016 | |||||||||||||||||||||||||||||||
| total stockholder’s deficit | -75,543,000 | ||||||||||||||||||||||||||||||
| total liabilities and stockholder’s deficit | 152,233,000 | ||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||
| research and development | 6,689,000 | ||||||||||||||||||||||||||||||
| general and administrative | 4,819,000 | ||||||||||||||||||||||||||||||
| depreciation and amortization | 218,000 | ||||||||||||||||||||||||||||||
| total operating expenses | 11,726,000 | ||||||||||||||||||||||||||||||
| income from operations | -11,726,000 | ||||||||||||||||||||||||||||||
| other income: | |||||||||||||||||||||||||||||||
| other income | 5,000 | ||||||||||||||||||||||||||||||
| income before taxes | -11,731,000 | ||||||||||||||||||||||||||||||
| benefit for income taxes | -7,251,000 | ||||||||||||||||||||||||||||||
| net income and comprehensive loss | -4,480,000 | ||||||||||||||||||||||||||||||
| net income per share | -270 | ||||||||||||||||||||||||||||||
| weighted-average shares outstanding used to compute basic and diluted net income per share | 16,527,000,000 |
We provide you with 20 years of balance sheets for Evolus stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Evolus. Explore the full financial landscape of Evolus stock with our expertly curated balance sheets.
The information provided in this report about Evolus stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.